# Concord Medical Services Holdings Ltd: Form 20-F for the period ended Dec 31, 2024

- Company: [Concord Medical Services Holdings Ltd](/companies/ccm.md) (CIK 1472072)
- Form: 20-F
- Filed: 2025-04-25
- Accepted by EDGAR: Apr 25, 2025, 09:20 ET
- Period: 2024-12-31
- Accession: 0001410578-25-000907
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1472072/000141057825000907/ccm-20241231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1472072/000141057825000907/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2024-01-01 to 2024-12-31 | $51.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months, 2024-01-01 to 2024-12-31 | $63.4m | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2024-01-01 to 2024-12-31 | −$10.8m | us-gaap:GrossProfit |
| Operating income | 12 months, 2024-01-01 to 2024-12-31 | −$72.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2024-01-01 to 2024-12-31 | $26.5m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months, 2024-01-01 to 2024-12-31 | −$2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | −$42.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | −$0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | −$0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2024-01-01 to 2024-12-31 | 131,053,858 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | −$54.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-01-01 to 2024-12-31 | $20.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-12-31 | $29.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-12-31 | $134.8m | us-gaap:AssetsCurrent |
| Total assets | at 2024-12-31 | $921.5m | us-gaap:Assets |
| Current liabilities | at 2024-12-31 | $291.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-12-31 | $699.9m | us-gaap:Liabilities |
| Long-term debt | at 2024-12-31 | $369.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-12-31 | $52.5m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2024-12-31 | $89.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2024-12-31 | −$312.4m | us-gaap:StockholdersEquity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1472072/000141057825000907/ccm-20241231x20f.htm

Filed Apr 25, 2025.
Source: SEC EDGAR, the filing index for accession 0001410578-25-000907. Last ingested by Listed: Oct 24, 2026, 15:08 ET. No prices; not investment advice.
